The American Food and Drug Administration has made it clear to pharmaceutical company PPD Inc. that they must conduct further tests on a diabetes drug being co-developed with Takeda Pharmaceuticals.
The news, released yesterday, is a blow for both of the companies. Aloglipti, had it been approved, would have earned PPD a £25 million milestone payment from Takeda.
The FDA is reviewing Alogliptin under fresh diabetes drug standards and safety guidelines. The FDA and the pharmaceutical industry came under heavy criticism when Avandia was found to increase the risk of heart problems amongst people with diabetes .
The FDA require the submission of a further cardiovascular safety study in the case of Aloglipti, which could delay approval by years.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…